Information Provided By: 
Fly News Breaks for October 3, 2018
ESRX, CI
Oct 3, 2018 | 06:25 EDT
Goldman Sachs analyst Stephen Tanal added Buy-rated Cigna (CI) to his firm's Conviction List and raised his price target for the shares to $250 from $227. After revisiting the company's fundamental story, the analyst continues to believe Cigna is well positioned to take share of the U.S. commercial market. He believes fundamentals support a higher standalone multiple. Further, while not taking a view on the Express Scripts (ESRX) deal closing, Tanal believes the combined company could reach its targeted leverage ratio earlier than expected.
News For CI;ESRX From the Last 2 Days
There are no results for your query CI;ESRX
